Skip to main content
Erschienen in: Journal of Neuro-Oncology 1/2016

12.03.2016 | Laboratory Investigation

MiR-519a functions as a tumor suppressor in glioma by targeting the oncogenic STAT3 pathway

verfasst von: Li Hong, Liu Ya-wei, Wang Hai, Zhou Qiang, Li Jun-jie, Annie Huang, Qi Song-tao, Lu Yun-tao

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Glioblastoma (GBM) is among the most aggressive primary brain tumors, with a median survival rate of 12–15 months. MicroRNAs have been implicated in GBM development as oncogenes or tumor suppressors. In this study, we demonstrated that miR-519a expression was frequently downregulated in GBM specimens and cell lines, and that low-levels miR-519a expression significantly correlated with poor outcomes associated with GBM. Analysis of The Cancer Genome Atlas also demonstrated that low miR-519a expression can predict poor clinical outcomes in classical and proneural GBM subtypes. Functionally, re-expression of miR-519a effectively reduced GBM cell proliferation, migration, and invasion. Mechanistically, we confirmed that the signal transducer and activator of transcription 3 (STAT3) 3′-UTR was a putative target of miR-519a, and that re-expression of STAT3 abrogated miR-519a function in GBM cells. Furthermore, we found that STAT3 expression negatively correlated with that of miR-519a in human GBM tissues. These results elucidated the prognostic value and tumor-suppressor role of miR-519a in GBM and further suggested it as a potential therapeutic target for GBM treatment.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Ng K, Kim R, Kesari S, Carter B, Chen CC (2012) Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights. J Neurooncol 107:1–12CrossRefPubMed Ng K, Kim R, Kesari S, Carter B, Chen CC (2012) Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights. J Neurooncol 107:1–12CrossRefPubMed
3.
4.
Zurück zum Zitat Brantley EC, Benveniste EN (2008) Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res 6:675–684CrossRefPubMed Brantley EC, Benveniste EN (2008) Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res 6:675–684CrossRefPubMed
5.
Zurück zum Zitat Lee K, Byun K, Hong W, Chuang HY, Pack CG, Bayarsaikhan E, Paek SH, Kim H, Shin HY, Ideker T, Lee B (2013) Proteome-wide discovery of mislocated proteins in cancer. Genome Res 23:1283–1294CrossRefPubMedPubMedCentral Lee K, Byun K, Hong W, Chuang HY, Pack CG, Bayarsaikhan E, Paek SH, Kim H, Shin HY, Ideker T, Lee B (2013) Proteome-wide discovery of mislocated proteins in cancer. Genome Res 23:1283–1294CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Dasgupta A, Raychaudhuri B, Haqqi T, Prayson R, Van Meir EG, Vogelbaum M, Haque SJ (2009) Stat3 activation is required for the growth of U87 cell-derived tumours in mice. Eur J Cancer 45:677–684CrossRefPubMed Dasgupta A, Raychaudhuri B, Haqqi T, Prayson R, Van Meir EG, Vogelbaum M, Haque SJ (2009) Stat3 activation is required for the growth of U87 cell-derived tumours in mice. Eur J Cancer 45:677–684CrossRefPubMed
7.
Zurück zum Zitat Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ (2002) Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 21:8404–8413CrossRefPubMed Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ (2002) Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 21:8404–8413CrossRefPubMed
8.
Zurück zum Zitat Senft C, Priester M, Polacin M, Schroder K, Seifert V, Kogel D, Weissenberger J (2011) Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells. J Neurooncol 101:393–403CrossRefPubMed Senft C, Priester M, Polacin M, Schroder K, Seifert V, Kogel D, Weissenberger J (2011) Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells. J Neurooncol 101:393–403CrossRefPubMed
9.
Zurück zum Zitat Lo HW, Cao X, Zhu H, Ali-Osman F (2008) Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res 14:6042–6054CrossRefPubMedPubMedCentral Lo HW, Cao X, Zhu H, Ali-Osman F (2008) Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res 14:6042–6054CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Lau J, Ilkhanizadeh S, Wang S, Miroshnikova YA, Salvatierra NA, Wong RA, Schmidt C, Weaver VM, Weiss WA, Persson AI (2015) STAT3 blockade inhibits radiation-induced malignant progression in glioma. Cancer Res 75:4302–4311CrossRefPubMed Lau J, Ilkhanizadeh S, Wang S, Miroshnikova YA, Salvatierra NA, Wong RA, Schmidt C, Weaver VM, Weiss WA, Persson AI (2015) STAT3 blockade inhibits radiation-induced malignant progression in glioma. Cancer Res 75:4302–4311CrossRefPubMed
12.
13.
Zurück zum Zitat Wei J, Wang F, Kong LY, Xu S, Doucette T, Ferguson SD, Yang Y, McEnery K, Jethwa K, Gjyshi O, Qiao W, Levine NB, Lang FF, Rao G, Fuller GN, Calin GA, Heimberger AB (2013) miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res 73:3913–3926CrossRefPubMedPubMedCentral Wei J, Wang F, Kong LY, Xu S, Doucette T, Ferguson SD, Yang Y, McEnery K, Jethwa K, Gjyshi O, Qiao W, Levine NB, Lang FF, Rao G, Fuller GN, Calin GA, Heimberger AB (2013) miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res 73:3913–3926CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Kim TM, Huang W, Park R, Park PJ, Johnson MD (2011) A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. Cancer Res 71:3387–3399CrossRefPubMedPubMedCentral Kim TM, Huang W, Park R, Park PJ, Johnson MD (2011) A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. Cancer Res 71:3387–3399CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Kim TH, Kim YK, Kwon Y, Heo JH, Kang H, Kim G, An HJ (2010) Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology 57:734–743CrossRefPubMed Kim TH, Kim YK, Kwon Y, Heo JH, Kang H, Kim G, An HJ (2010) Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology 57:734–743CrossRefPubMed
16.
Zurück zum Zitat Ward A, Shukla K, Balwierz A, Soons Z, Konig R, Sahin O, Wiemann S (2014) MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J Pathol 233:368–379CrossRefPubMedPubMedCentral Ward A, Shukla K, Balwierz A, Soons Z, Konig R, Sahin O, Wiemann S (2014) MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J Pathol 233:368–379CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Wang W, Zhao LJ, Tan YX, Ren H, Qi ZT (2012) Identification of deregulated miRNAs and their targets in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol 18:5442–5453CrossRefPubMedPubMedCentral Wang W, Zhao LJ, Tan YX, Ren H, Qi ZT (2012) Identification of deregulated miRNAs and their targets in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol 18:5442–5453CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Abdelmohsen K, Kim MM, Srikantan S, Mercken EM, Brennan SE, Wilson GM, Cabo R, Gorospe M (2010) miR-519 suppresses tumor growth by reducing HuR levels. Cell Cycle 9:1354–1359CrossRefPubMedPubMedCentral Abdelmohsen K, Kim MM, Srikantan S, Mercken EM, Brennan SE, Wilson GM, Cabo R, Gorospe M (2010) miR-519 suppresses tumor growth by reducing HuR levels. Cell Cycle 9:1354–1359CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A (2004) Identification of mammalian microRNA host genes and transcription units. Genome Res 14:1902–1910CrossRefPubMedPubMedCentral Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A (2004) Identification of mammalian microRNA host genes and transcription units. Genome Res 14:1902–1910CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Li M, Lee KF, Lu Y, Clarke I, Shih D, Eberhart C, Collins VP, Van Meter T, Picard D, Zhou L, Boutros PC, Modena P, Liang ML, Scherer SW, Bouffet E, Rutka JT, Pomeroy SL, Lau CC, Taylor MD, Gajjar A, Dirks PB, Hawkins CE, Huang A (2009) Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell 16:533–546CrossRefPubMedPubMedCentral Li M, Lee KF, Lu Y, Clarke I, Shih D, Eberhart C, Collins VP, Van Meter T, Picard D, Zhou L, Boutros PC, Modena P, Liang ML, Scherer SW, Bouffet E, Rutka JT, Pomeroy SL, Lau CC, Taylor MD, Gajjar A, Dirks PB, Hawkins CE, Huang A (2009) Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell 16:533–546CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Song X, Andrew Allen R, Terence Dunn S, Fung KM, Farmer P, Gandhi S, Ranjan T, Demopoulos A, Symons M, Schulder M, Li JY (2011) Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma. Int J Clin Exp Pathol 4:651–660PubMedPubMedCentral Song X, Andrew Allen R, Terence Dunn S, Fung KM, Farmer P, Gandhi S, Ranjan T, Demopoulos A, Symons M, Schulder M, Li JY (2011) Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma. Int J Clin Exp Pathol 4:651–660PubMedPubMedCentral
22.
Zurück zum Zitat Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Cancer Genome Atlas Research N (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110CrossRefPubMedPubMedCentral Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Cancer Genome Atlas Research N (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Uhlmann S, Zhang JD, Schwager A, Mannsperger H, Riazalhosseini Y, Burmester S, Ward A, Korf U, Wiemann S, Sahin O (2010) miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene 29:4297–4306CrossRefPubMed Uhlmann S, Zhang JD, Schwager A, Mannsperger H, Riazalhosseini Y, Burmester S, Ward A, Korf U, Wiemann S, Sahin O (2010) miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene 29:4297–4306CrossRefPubMed
24.
Zurück zum Zitat Lu Y, Wang L, He M, Huang W, Li H, Wang Y, Kong J, Qi S, Ouyang J, Qiu X (2012) Nix protein positively regulates NF-kappaB activation in gliomas. PLoS ONE 7:e44559CrossRefPubMedPubMedCentral Lu Y, Wang L, He M, Huang W, Li H, Wang Y, Kong J, Qi S, Ouyang J, Qiu X (2012) Nix protein positively regulates NF-kappaB activation in gliomas. PLoS ONE 7:e44559CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Li R, Gao K, Luo H, Wang X, Shi Y, Dong Q, Luan W, You Y (2014) Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma. J Exp Clin Cancer Res 33:9CrossRefPubMedPubMedCentral Li R, Gao K, Luo H, Wang X, Shi Y, Dong Q, Luan W, You Y (2014) Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma. J Exp Clin Cancer Res 33:9CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H (2011) The brain tumor microenvironment. Glia 59:1169–1180CrossRefPubMed Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H (2011) The brain tumor microenvironment. Glia 59:1169–1180CrossRefPubMed
27.
Zurück zum Zitat Lathia JD, Heddleston JM, Venere M, Rich JN (2011) Deadly teamwork: neural cancer stem cells and the tumor microenvironment. Cell Stem Cell 8:482–485CrossRefPubMedPubMedCentral Lathia JD, Heddleston JM, Venere M, Rich JN (2011) Deadly teamwork: neural cancer stem cells and the tumor microenvironment. Cell Stem Cell 8:482–485CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Flor I, Bullerdiek J (2012) The dark side of a success story: microRNAs of the C19MC cluster in human tumours. J Pathol 227:270–274CrossRefPubMed Flor I, Bullerdiek J (2012) The dark side of a success story: microRNAs of the C19MC cluster in human tumours. J Pathol 227:270–274CrossRefPubMed
29.
30.
Zurück zum Zitat Brantley EC, Nabors LB, Gillespie GY, Choi YH, Palmer CA, Harrison K, Roarty K, Benveniste EN (2008) Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin Cancer Res 14:4694–4704CrossRefPubMed Brantley EC, Nabors LB, Gillespie GY, Choi YH, Palmer CA, Harrison K, Roarty K, Benveniste EN (2008) Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin Cancer Res 14:4694–4704CrossRefPubMed
31.
Zurück zum Zitat Lin GS, Yang LJ, Wang XF, Chen YP, Tang WL, Chen L, Lin ZX (2014) STAT3 Tyr705 phosphorylation affects clinical outcome in patients with newly diagnosed supratentorial glioblastoma. Med Oncol 31:924CrossRefPubMed Lin GS, Yang LJ, Wang XF, Chen YP, Tang WL, Chen L, Lin ZX (2014) STAT3 Tyr705 phosphorylation affects clinical outcome in patients with newly diagnosed supratentorial glioblastoma. Med Oncol 31:924CrossRefPubMed
32.
Zurück zum Zitat Birner P, Toumangelova-Uzeir K, Natchev S, Guentchev M (2010) STAT3 tyrosine phosphorylation influences survival in glioblastoma. J Neurooncol 100:339–343CrossRefPubMed Birner P, Toumangelova-Uzeir K, Natchev S, Guentchev M (2010) STAT3 tyrosine phosphorylation influences survival in glioblastoma. J Neurooncol 100:339–343CrossRefPubMed
33.
Zurück zum Zitat Zhong Z, Wen Z, Darnell JE Jr (1994) Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264:95–98CrossRefPubMed Zhong Z, Wen Z, Darnell JE Jr (1994) Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264:95–98CrossRefPubMed
34.
Zurück zum Zitat Lee MH, Yang HY (2003) Regulators of G1 cyclin-dependent kinases and cancers. Cancer Metastasis Rev 22:435–449CrossRefPubMed Lee MH, Yang HY (2003) Regulators of G1 cyclin-dependent kinases and cancers. Cancer Metastasis Rev 22:435–449CrossRefPubMed
35.
Zurück zum Zitat Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, Kondo S, Priebe W, Kondo Y (2007) A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26:2435–2444CrossRefPubMed Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, Kondo S, Priebe W, Kondo Y (2007) A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26:2435–2444CrossRefPubMed
37.
Zurück zum Zitat Li Z, Du L, Li C, Wu W (2013) Human chorionic gonadotropin beta induces cell motility via ERK1/2 and MMP-2 activation in human glioblastoma U87MG cells. J Neurooncol 111:237–244CrossRefPubMed Li Z, Du L, Li C, Wu W (2013) Human chorionic gonadotropin beta induces cell motility via ERK1/2 and MMP-2 activation in human glioblastoma U87MG cells. J Neurooncol 111:237–244CrossRefPubMed
Metadaten
Titel
MiR-519a functions as a tumor suppressor in glioma by targeting the oncogenic STAT3 pathway
verfasst von
Li Hong
Liu Ya-wei
Wang Hai
Zhou Qiang
Li Jun-jie
Annie Huang
Qi Song-tao
Lu Yun-tao
Publikationsdatum
12.03.2016
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 1/2016
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-016-2095-z

Weitere Artikel der Ausgabe 1/2016

Journal of Neuro-Oncology 1/2016 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.